The global colloids (Blood Plasma) market size was valued at USD 3.61 billion in 2025 and is projected to grow from USD 3.8 billion in 2026 to USD 5.75 billion by 2034 at a CAGR of 5.3% during the forecast period 2026-2034. North America dominated the colloids (Blood Plasma) market with a market share of 38.4% in 2025.
Colloids refer to substances dispersed evenly in another substance. In the context of blood plasma, colloids are primarily proteins such as albumin, globulins, and fibrinogen. These proteins contribute to the osmotic pressure of blood, helping to maintain fluid balance between blood vessels and tissues. Albumin, the most abundant plasma protein, assists in transporting hormones, fatty acids, and drugs, while globulins play a critical role in immune function by carrying antibodies.
Download a Free Sample To learn more about this report,
Growing Adoption of Plasma-Derived Therapies and Albumin for Critical Care
The colloids (blood plasma) market trends are increasingly driven by the growing use of plasma-derived products, particularly human albumin, in critical care, trauma, liver disease, and intensive care units (ICUs). Albumin remains one of the most widely used natural colloid solutions for maintaining blood volume in patients with severe burns, shock, sepsis, and major surgeries. Rising demand for plasma-derived medicinal products (PDMPs), coupled with increasing plasma collection and fractionation capacity, is supporting market growth. According to the World Health Organization (WHO), plasma-derived therapies are considered essential medicines for treating several life-threatening conditions, encouraging countries to strengthen plasma collection and manufacturing capabilities.
Rising Investments in Plasma Collection and Blood Supply Infrastructure
The colloids (blood plasma) market is witnessing steady growth due to increasing investments in blood collection infrastructure and plasma donation programs. Governments, healthcare organizations, and plasma therapy manufacturers are expanding donation centers and improving collection technologies to ensure a stable supply of plasma for therapeutic use. The growing prevalence of chronic diseases, surgical procedures, and immune-related disorders is further increasing the need for plasma-derived colloid products in healthcare settings.
Rising Demand for Critical Care and Trauma Management
The colloids (blood plasma) market growth is driven by the increasing demand for effective volume replacement therapies in critical care, trauma, emergency medicine, and major surgical procedures. Colloid solutions are widely used to restore blood volume, stabilize blood pressure, and maintain tissue perfusion in patients experiencing severe blood loss, burns, septic shock, and hypovolemia. The growing number of surgical procedures, rising incidence of road accidents, and increasing prevalence of chronic diseases requiring intensive care are further supporting market growth. The colloids (blood plasma) market growth is also fueled by expanding healthcare infrastructure, improved emergency medical services, and continuous advancements in plasma-derived therapies and critical care management.
Safety Concerns and Stringent Regulatory Requirements
The colloids (blood plasma) market faces significant restraints due to concerns regarding adverse reactions, coagulation disorders, kidney-related complications associated with certain synthetic colloids, and the risk of allergic responses. Regulatory authorities have introduced stricter guidelines governing the clinical use of specific colloid solutions, particularly hydroxyethyl starch products, limiting their application in certain patient populations. The colloids (blood plasma) market analysis also indicates that high manufacturing costs, complex plasma collection processes, and strict quality control requirements increase production expenses. In addition, the limited availability of plasma donations in some regions continues to challenge market expansion.
Growth in Plasma Fractionation and Advanced Critical Care Therapies
The increasing demand for plasma-derived therapeutics and advancements in plasma fractionation technologies are creating significant opportunities for the colloids (blood plasma) market. Manufacturers are investing in improved purification techniques, advanced plasma processing, and expanded plasma collection networks to enhance product availability and safety. The colloids (blood plasma) market analysis highlights growing applications in intensive care units, emergency medicine, liver disease management, and complex surgical procedures. Rising healthcare investments, expanding hospital infrastructure, and increasing demand for advanced biologics are expected to create long-term growth opportunities for market participants.
Ensuring Plasma Supply and Maintaining Product Safety
One of the major challenges facing the colloids (blood plasma) market is maintaining a stable supply of high-quality plasma while ensuring stringent safety standards throughout collection, processing, and distribution. Dependence on voluntary plasma donations, complex manufacturing procedures, and rigorous regulatory oversight can limit product availability. The colloids (blood plasma) market growth is also affected by increasing production costs, evolving clinical guidelines, and the need for continuous monitoring of product efficacy and safety. Balancing growing clinical demand with sustainable plasma collection, regulatory compliance, and cost-effective manufacturing remains a key challenge for companies operating in the global colloids (blood plasma) market.
Request Customizationto receive a tailored report.
Natural Type Colloids Dominated the Market with 63.7% Share in 2025
The natural type colloids segment accounted for the largest share of the global colloids (blood plasma) market at 63.7% in 2025, driven by their superior biocompatibility, effective plasma volume expansion, and widespread use in critical care, trauma management, and surgical procedures.
Synthetic type colloids continue to witness steady demand due to their cost-effectiveness, longer shelf life, and availability for rapid fluid resuscitation. They are commonly used in emergency medicine and perioperative care where immediate restoration of blood volume is required.
Hypovolemic Shock is Projected to Register the Fastest Growth at a CAGR of 7.18%
The hypovolemic shock segment is expected to expand at the highest CAGR of 7.18% during 2026–2034, supported by the rising incidence of trauma, severe dehydration, surgical complications, and emergency conditions requiring rapid plasma volume replacement.
Massive blood or plasma loss remains a major application area owing to the increasing number of surgical procedures, accident-related injuries, and hemorrhagic emergencies requiring effective volume expansion. Extensive burns continue to drive demand for colloid solutions to maintain circulatory stability and support fluid management in burn patients. Other applications, including critical care and postoperative fluid therapy, are also contributing to the sustained adoption of blood plasma colloids across healthcare settings.
Speak to an Analystto discuss market opportunities.
North America accounted for a 38.4% colloids (blood plasma) market share, valued at USD 1.39 billion in 2025. The region's growth is driven by advanced healthcare infrastructure, increasing demand for plasma-derived therapies, rising surgical procedures, and the growing prevalence of chronic and trauma-related conditions requiring volume replacement. Strong investments in healthcare, high plasma collection capacity, and continuous advancements in critical care medicine continue to support regional colloids (blood plasma) market growth.
The United States market accounted for the largest share of the North American market in 2025. Growth is driven by increasing demand for plasma-derived products, expanding hospital and emergency care services, rising surgical procedures, and the presence of leading plasma collection and biopharmaceutical companies. Continuous investment in healthcare innovation further strengthens the country's market position.
Canada market is witnessing steady market growth due to increasing healthcare expenditure, growing demand for critical care therapies, expanding plasma collection initiatives, and rising adoption of advanced blood management practices across hospitals and healthcare facilities.
Europe market accounted for 27.6% of the global colloids (blood plasma) market, reaching USD 1.0 billion in 2025. Market growth is supported by well-established healthcare systems, increasing demand for plasma-derived therapeutics, rising surgical and emergency care procedures, and growing investments in blood transfusion and critical care services. Strong regulatory standards and expanding plasma research continue to drive regional demand.
The United Kingdom market is witnessing steady market growth owing to increasing demand for plasma-derived medicines, expanding hospital infrastructure, rising surgical volumes, and growing government support for improving blood and plasma collection services.
Germany market represents one of the largest markets in Europe, driven by its advanced healthcare infrastructure, increasing adoption of plasma-derived therapies, growing investments in biotechnology, and rising demand for critical care and emergency medical treatments.
Asia Pacific market accounted for 22.3% of the global colloids (blood plasma) market, valued at USD 0.81 billion in 2025, and is projected to register the fastest CAGR of 8.12% during the forecast period. The market is expanding due to improving healthcare infrastructure, increasing healthcare expenditure, rising prevalence of chronic diseases, and growing demand for advanced critical care treatments. Expanding plasma collection networks and increasing awareness of plasma-derived therapies continue to support regional market growth.
Japan market is witnessing steady market growth due to its advanced healthcare system, increasing demand for plasma-derived therapeutics, rising elderly population, and continuous investments in biotechnology and critical care services.
China market accounted for the largest share of the Asia Pacific market in 2025. Growth is supported by expanding healthcare infrastructure, increasing plasma collection activities, rising hospital admissions, growing demand for plasma-derived products, and continuous government investments in healthcare modernization.
The Middle East & Africa market represented 4.9% of the global colloids (blood plasma) market, totaling USD 0.18 billion in 2025. Rising healthcare investments, expanding hospital infrastructure, increasing demand for emergency and critical care services, and improving access to advanced plasma therapies are supporting regional market growth.
The UAE market is a key market in the Middle East, driven by increasing investments in advanced healthcare facilities, expanding critical care services, rising surgical procedures, and growing adoption of plasma-derived therapies across hospitals.
The African market is witnessing gradual growth, supported by improving healthcare infrastructure, increasing government investments in blood transfusion services, rising awareness of plasma therapies, and expanding access to emergency medical care. Countries such as South Africa, Egypt, and Kenya are creating long-term growth opportunities for market participants.
Unlock Regional Insightsto access country-level data, & regional trends.
Customize This Report to Match Your Strategic Objectives
Author's Details
Healthcare Lead
Debashree Bora is a Healthcare Lead with over 7 years of industry experience, specializing in Healthcare IT. She provides comprehensive market insights on digital health, electronic medical records, telehealth, and healthcare analytics. Debashree’s research supports organizations in adopting technology-driven healthcare solutions, improving patient care, and achieving operational efficiency in a rapidly transforming healthcare ecosystem.
We are featured on:
sales@straitsresearch.com